Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CytRx RheothRx agreement with Wellcome will pay 15% royalties; Wellcome has paid $9 mil. to date.

Executive Summary

CYTRX TO RECEIVE 15% "OFF THE TOP" OF RHEOTHRx SALES by Burroughs Wellcome under a licensing agreement signed in April 1990 for the adjunct to thrombolytic therapy post-MI, CytRx President and CEO Jack Luchese told a Raymond James healthcare conference in St. Petersburg, Fla. March 8. "Wellcome will supply its own materials in the U.S.," he noted. "Our third-party royalties are modest, so we will retain about 93% of everything we collect." Sales outside the U.S. will provide a 10% royalty to the Norcross, Ga. biotech firm.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel